Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer

Clinical Cancer Research

Volumn 7, Issue 8, 2001, Pages 2396-2404

  Schmalfeldt, Barbara ^a   Prechtel, Dieter ^a   Härting, Kathrin ^a   Späthe, Kerstin ^a   Rutke, Stefan ^a   Konik, Elisabeth ^a   Fridman, Rafael ^b   Berger, Ursula ^a   Kuhn, Walther ^a   Lengyel, Ernst ^a,c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; UROKINASE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CARCINOGENESIS; CLINICAL ARTICLE; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; MEDICAL SOCIETY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; ZYMOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; DISEASE PROGRESSION; ENDOPEPTIDASES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; OVARY; PLASMINOGEN ACTIVATOR INHIBITOR 1; STATISTICS; URINARY PLASMINOGEN ACTIVATOR;

EID: 0034892043     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. The hallmarks of cancer
2. The role of proteolytic enzymes in the pathology of epithelial ovarian carcinoma
3. The urokinase-type plasminogen activator system in cancer metastasis: A review
4. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: Prognostic relevance and target for therapy
5. Matrix metalloproteinases
6. Matrix metalloproteinases: Biologic activity and clinical implications
7. r 92, 000 gelatinase release correlates with the metastatic phenotype in transformed rat embryo cells
8. Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma
9. Characterization of gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: Purification of matrix metalloproteinase 2
10. Production of extracellular matrix-degrading proteinases by primary cultures of human epithelial ovarian carcinoma cells
11. Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression and synthetic matrix metalloproteinase-2 inhibitor binding in ovarian carcinomas and tumor cell lines
12. Expression and activity of MMPs and their regulators in ovarian cancer
13. Tissue and serum metalloproteinase (MMP-2) expression in advanced ovarian serous cystadenocarcinomas: Clinical and prognostic implications
14. 72-Kilodalton type IV collagenase, type IV collagen, and Ki67 antigen in serous tumors or the ovary: A clinicopathologic, immunohistochemical, and serological study
15. Gelatinase A-immunoreactive protein in ovarian lesions- prognostic value in epithelial ovarian cancer
16. Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2
17. Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc
18. Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors
19. The plasminogen-activation system in ovarian tumors
20. High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer
21. r 92, 000 type IV collagenase expression in a squamous cell carcinoma cell line by fibroblasts
22. Activity of type IV collagenases in benign and malignant breast disease
23. Rac1 in human breast cancer: Overexpression, mutation analysis, and characterization of a new isoform, Rac1b
24. Detergent-activation of latent collagenase and resolution of its component molecules
25. Increased type-IV collagenase (MMP-2 and MMP-9) activity following preoperative radiotherapy in rectal cancer
26. Assay of matrix metalloproteinases types 1, 2, 3, and 9 in breast cancer
27. Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion
28. Evaluation of basement membrane components and the 72 kDa type IV collagenase in serous tumors of the ovary
29. Enhanced production of matrix metalloproteinases and activation of matrix metalloproteinase 2 (gelatinase A) in human gastric carcinomas
30. Positive correlation between inhibitors of matrix metalloproteinase 1 and matrix metalloproteinases in malignant ovarian tumor tissues
31. Distinct pattern of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 mRNA expression in human colorectal cancer and liver metastases
32. Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma
33. Tumor progression: Defining the soil round the tumor seed
34. The biology of ovarian cancer
35. Plasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients
36. Proteinase requirements of epidermal growth factor-induced ovarian cancer cell invasion
37. Control of type IV collagenase activity by components of the urokinase-plasmin system: A regulatory mechanism with cell-bound reactants
38. Stimulation of 92-kDA gelatinase B promoter activity by ras is mitogen-activated protein kinase kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences
39. Activation mechanisms of the urokinase-type plasminogen activator promoter by hepatocyte growth factor/scatter factor
40. The Ap-1 site and MMP gene regulation: What is all the fuss about?